Following The Money: Institution’s Growing Stake In Bio-Key International Inc (NASDAQ: BKYI)

Bio-Key International Inc (BKYI) concluded trading on Wednesday at a closing price of $2.28, with 196.03 million shares of worth about $446.94 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 23.91% during that period and on January 15, 2025 the price saw a gain of about 66.42%. Currently the company’s common shares owned by public are about 3.11M shares, out of which, 2.33M shares are available for trading.

Stock saw a price change of 34.91% in past 5 days and over the past one month there was a price change of 128.00%. Year-to-date (YTD), BKYI shares are showing a performance of 33.33% which increased to 12.32% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.52 but also hit the highest price of $3.22 during that period. The average intraday trading volume for Bio-Key International Inc shares is 2.39 million. The stock is currently trading 65.84% above its 20-day simple moving average (SMA20), while that difference is up 94.53% for SMA50 and it goes to 64.21% higher than SMA200.

Bio-Key International Inc (NASDAQ: BKYI) currently have 3.11M outstanding shares and institutions hold larger chunk of about 8.85% of that.

The stock has a current market capitalization of $7.12M and its 3Y-monthly beta is at 0.02. It has posted earnings per share of -$7.69 in the same period. It has Quick Ratio of 0.71 while making debt-to-equity ratio of 18.92. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BKYI, volatility over the week remained 47.34% while standing at 27.91% over the month.

Analysts are in expectations that Bio-Key International Inc (BKYI) stock would likely to be making an EPS of -0.35 in the current quarter, while forecast for next quarter EPS is 0 and it is -1.56 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.35 which is -0.35 at the higher side of the target for the same. Stock’s fiscal year EPS is expected to rise by 83.76% while it is estimated to increase by 16.13% in next year.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Maxim Group on March 26, 2021 offering a Buy rating for the stock and assigned a target price of $6 to it.

Most Popular

Related Posts